Search research articles
Contact Us
Filters
Showing results (221-230 of 262) with videos related to
Page
of 27
Sort By:
Med (New York, N.Y.)
|
July 10, 2024
A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer
Ning Li, Meng Qiu, Yanqiao Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 21, 2022
Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China
Shun Lu, Qing Zhou, Xiaoqing Liu, et al.
The Lancet. Oncology
|
October 24, 2023
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Sun Young Rha, Do-Youn Oh, Patricio Yañez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 11, 2018
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With
Shukui Qin, Jin Li, Liwei Wang, et al.
Nature Medicine
|
May 16, 2025
Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial
Caicun Zhou, Xiaorong Dong, Gongyan Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2021
An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline <i>BRCA1/2</i> Mutation and Platinum-sensitive Recurrent Ovarian Cancer
Ning Li, Hualei Bu, Jihong Liu, et al.
The Lancet. Oncology
|
February 18, 2017
Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial
Pin Zhang, Tao Sun, Qingyuan Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2021
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
Shukui Qin, Feng Bi, Shanzhi Gu, et al.
JAMA
|
December 5, 2023
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial
Jianming Xu, Haiping Jiang, Yueyin Pan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 30, 2025
A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Geoffrey Ku, Lin Shen, Farshid Dayyani, et al.
Page
of 27
Search research articles
Search
Showing results (221-230 of 262) with videos related to
Sort By:
Page
of 27
Med (New York, N.Y.)
|
July 10, 2024
A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer
Ning Li, Meng Qiu, Yanqiao Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 21, 2022
Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China
Shun Lu, Qing Zhou, Xiaoqing Liu, et al.
The Lancet. Oncology
|
October 24, 2023
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
Sun Young Rha, Do-Youn Oh, Patricio Yañez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 11, 2018
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With
Shukui Qin, Jin Li, Liwei Wang, et al.
Nature Medicine
|
May 16, 2025
Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial
Caicun Zhou, Xiaorong Dong, Gongyan Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2021
An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline <i>BRCA1/2</i> Mutation and Platinum-sensitive Recurrent Ovarian Cancer
Ning Li, Hualei Bu, Jihong Liu, et al.
The Lancet. Oncology
|
February 18, 2017
Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial
Pin Zhang, Tao Sun, Qingyuan Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2021
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
Shukui Qin, Feng Bi, Shanzhi Gu, et al.
JAMA
|
December 5, 2023
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial
Jianming Xu, Haiping Jiang, Yueyin Pan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 30, 2025
A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Geoffrey Ku, Lin Shen, Farshid Dayyani, et al.
Page
of 27